Economic evaluation of first-line treatments for metastatic renal cell carcinoma: A cost-effectiveness analysis in a health resource-limited setting

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Wu, Bin ^a   Dong, Baijun ^b   Xu, Yuejuan ^c   Zhang, Qiang ^d   Shen, Jinfang ^a   Chen, Huafeng ^a   Xue, Wei ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^d SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; EVEROLIMUS; FLUOROURACIL; INTERLEUKIN 2; MORPHINE SULFATE; PLACEBO; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT;

ANEMIA; ARTICLE; ASTHENIA; CANCER SURVIVAL; CHINA; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SURVIVAL RATE; THROMBOCYTOPENIA; COST BENEFIT ANALYSIS; ECONOMICS; KIDNEY TUMOR; METASTASIS; PATHOLOGY; STATISTICAL MODEL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CHINA; COST-BENEFIT ANALYSIS; HEALTH RESOURCES; HUMANS; KIDNEY NEOPLASMS; MODELS, ECONOMIC;

EID: 84863287548     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032530     Document Type: Article

References (34)

1. Rini BI, Campbell SC, Escudier B, (2009) Renal cell carcinoma. Lancet 373: 1119-1132.
2. Curti BD, (2004) Renal cell carcinoma. JAMA: the journal of the American Medical Association 292: 97-100.
3. Sengupta S, Zincke H, (2005) Lessons learned in the surgical management of renal cell carcinoma. Urology 66: 36-42.
4. Lam JS, Bergman J, Breda A, Schulam PG, (2008) Importance of surgical margins in the management of renal cell carcinoma. Nature clinical practice Urology 5: 308-317.
5. Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, et al. (2010) Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 375: 641-648.
6. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, et al. (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. The New England journal of medicine 338: 1272-1278.
7. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, et al. (2005) Immunotherapy for advanced renal cell cancer. Cochrane database of systematic reviews pp. CD001425.
8. Gore ME, De Mulder P, (2008) Establishing the role of cytokine therapy in advanced renal cell carcinoma. BJU international 101: 1063-1070.
9. Hutson TE, Quinn DI, (2005) Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Clinical genitourinary cancer 4: 181-186.
10. Sun M, Lughezzani G, Perrotte P, Karakiewicz PI, (2010) Treatment of metastatic renal cell carcinoma. Nature reviews Urology 7: 327-338.
11. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, et al. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111.
12. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England journal of medicine 356: 115-124.
13. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, et al. (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27: 3584-3590.
14. Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, et al. (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 28: 2144-2150.
15. Ravasio R, Ortega C, Sabbatini R, Porta C, (2011) Bevacizumab plus Interferon-alpha versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy: A Cost-Minimization Analysis. Clinical drug investigation 31: 507-517.
16. Hoyle M, Green C, Thompson-Coon J, Liu Z, Welch K, et al. (2010) Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research 13: 61-68.
17. Remak E, Charbonneau C, Negrier S, Kim ST, Motzer RJ, (2008) Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26: 3995-4000.
18. Chabot I, Rocchi A, (2010) How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research 13: 837-845.
19. Molina AM, Motzer RJ, (2011) Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. The oncologist 16 (Suppl 2): 45-50.
20. Wu B, Chen H, Shen J, Ye M, (2011) Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in china. Clinical therapeutics 33: 1446-1455.
21. Kielhorn A, Porter D, Diamantopoulos A, Lewis G, (2008) UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Current medical research and opinion 24: 2639-2650.
22. Sutent® Patient Assistance Program. http://www.chinacancernet.org.cn/Info/SortContentEn.asp?ID=31. Accessed 2011 August 8.
23. Barbui C, Dua T, van Ommeren M, Yasamy MT, Fleischmann A, et al. (2010) Challenges in Developing Evidence-Based Recommendations Using the GRADE Approach: The Case of Mental, Neurological, and Substance Use Disorders. Plos Medicine 7.
24. National Development and Reform Commission (NDRC). http://en.ndrc.gov.cn/. Accessed 2011 October 28.
25. Vickers MM, Choueiri TK, Rogers M, Percy A, Finch D, et al. (2010) Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 76: 430-434.
26. Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, et al. (2010) Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. British journal of cancer 102: 80-86.
27. List of Chinese administrative divisions by GDP per capita. http://en.wikipedia.org/wiki/List_of_Chinese_administrative_divisions_by_GDP_per_capita. Accessed 2011 October 28.
28. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B, (2004) Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research 7: 518-528.
29. Murray CJ, Evans DB, Acharya A, Baltussen RM, (2000) Development of WHO guidelines on generalized cost-effectiveness analysis. Health economics 9: 235-251.
30. Hougaard JL, Osterdal LP, Yu Y, (2011) The Chinese healthcare system: structure, problems and challenges. Applied health economics and health policy 9: 1-13.
31. Wagstaff A, Yip W, Lindelow M, Hsiao WC, (2009) China's health system and its reform: a review of recent studies. Health economics 18 (Suppl 2): S7-23.
32. Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, et al. (2010) Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health technology assessment 14: 1-184, iii-iv.
33. Benedict A, Figlin RA, Sandstrom P, Harmenberg U, Ullen A, et al. (2011) Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU international.
34. de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M, (2009) EORTC-GU group expert opinion on metastatic renal cell cancer. European journal of cancer 45: 765-773.